ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders
- Written by PR Newswire
BRISBANE, Calif., July 26, 2024 /PRNewswire/ -- ReviR Therapeutics, an AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, announced today that it has successfully completed a $30 million Series A financing, bringing the total raised so far to $54M, including the seed financing in 2021....














